Posted inUS_1

Where Does the Citric Acid Cycle Occur? Unveiling the Cellular Location of the Krebs Cycle

No Comments

The citric acid cycle, a pivotal metabolic process also recognized as the Krebs cycle or tricarboxylic acid (TCA) cycle, acts as a central hub within the cell. As depicted in Figure 1, the Krebs Cycle, this sequence of chemical reactions is orchestrated by eight enzymes. Except for succinate dehydrogenase, which uniquely resides on the inner mitochondrial membrane as part of the respiratory chain, all these enzymes are located within the mitochondrial matrix. This cycle serves as the primary gateway for aerobic metabolism, accommodating molecules that can be converted into acetyl groups or dicarboxylic acids. The regulation of the TCA cycle is meticulously controlled at three key enzymatic steps: those catalyzed by citrate synthase, isocitrate dehydrogenase, and alpha-ketoglutarate dehydrogenase. Beyond energy generation, the cycle is also crucial for supplying precursors essential for the biosynthesis of vital molecules like amino acids and cholesterol.1

Delving into the Location of the Citric Acid Cycle

While often associated with oxygen, it’s important to clarify that the citric acid cycle itself doesn’t directly require oxygen. Oxygen’s necessity comes into play during oxidative phosphorylation, the final stage of aerobic cellular respiration that follows the Krebs cycle. Prior to entering the cycle, energy-rich organic molecules—whether carbohydrates, lipids, or proteins—undergo initial breakdown. These molecules are processed into acetyl-CoA, a crucial molecule composed of an acetyl group (CH3CO-) and coenzyme A, an acyl carrier.

Glycolysis remains the preferred source for generating acetyl-CoA. Within the Krebs cycle, the acetyl group from acetyl-CoA is completely oxidized. The energy liberated during this oxidation is then harnessed to synthesize ATP, in conjunction with oxidative phosphorylation. In eukaryotic cells, the entire set of Krebs cycle reactions unfolds within the mitochondrial matrix. This matrix is a dense, aqueous environment enclosed by the inner mitochondrial membrane, rich in all the enzymes, coenzymes, and phosphates required for the cycle’s biochemical reactions. The Krebs cycle’s activity is finely tuned by the availability of its substrates, NAD+ and FAD. Conversely, high concentrations of NADH act as an inhibitor, regulating the cycle’s pace.

Citric Acid Cycle Location at the Cellular Level

Glucose metabolism initiates in the cytoplasm (cytosol) through glycolysis, an anaerobic process. Glycolysis produces a small amount of ATP and pyruvate, a three-carbon compound. Once pyruvate is transported into the mitochondria, the pyruvate dehydrogenase complex (PDC), located in the mitochondrial matrix, catalyzes its conversion into acetyl-CoA and carbon dioxide (CO2). Each acetyl-CoA molecule that enters the TCA cycle can generate approximately 12 ATP molecules through subsequent oxidative phosphorylation. The PDC itself is a complex of three protein subunits requiring five cofactors for its enzymatic function, enabling precise regulation.

Under conditions of high blood sugar, glucose-derived pyruvate becomes the primary source of acetyl-CoA. However, during fasting or starvation, beta-oxidation of fatty acids becomes a significant contributor to acetyl-CoA production. Within the TCA cycle, acetyl-CoA undergoes complete oxidation to CO2 in eight sequential steps. The energy released from these reactions is captured and stored in the reduced forms of electron carriers: NADH+H+, FADH2, and GTP. NADH+H+ and FADH2 then donate their electrons to the electron transport chain (also located in the inner mitochondrial membrane), ultimately leading to ATP synthesis via oxidative phosphorylation.2 Importantly, intermediates of the TCA cycle are not only crucial for energy production but also serve as precursors for both catabolic and anabolic pathways, linking the cycle to various metabolic processes like glycolysis, gluconeogenesis, ketogenesis, and lipogenesis.3

The pyruvate dehydrogenase complex (PDC) activity, crucial for providing acetyl-CoA to the citric acid cycle, is governed by three primary regulatory mechanisms: covalent modification, allosteric regulation, and transcriptional regulation. Covalent modification, the primary regulatory form, involves phosphorylation of the pyruvate decarboxylase subunit of PDC. Phosphorylation reduces PDC activity, while increased ADP or pyruvate levels (indicating a need for more acetyl-CoA in the TCA cycle) downregulate PDC phosphorylation. Calcium ions stimulate phosphatase activity, which in turn dephosphorylates PDC, activating it. Allosteric regulation involves direct substrate activation or product inhibition. For example, excess acetyl-CoA or NADH directly inhibits PDC, while increased CoASH (acetyl-CoA precursor) or NAD+ activates it. Transcriptional regulation, the final mechanism, adjusts the number of PDC enzymes produced depending on fed or fasted states. Insulin promotes enzyme production in the fed state, while fasting reduces it.4

Developmental Significance of the Krebs Cycle

The Krebs cycle’s importance extends beyond basic energy production, playing a vital role in development. The energy generated by this metabolic pathway is essential for the proper development of the endothelial system, which guides the formation of blood and lymphatic vessels. Disruptions in the Krebs cycle during fetal development can have serious consequences, potentially leading to cardiac issues at birth. Alterations in the cycle can elevate cortisol levels, disrupting placental metabolism and fetal development, including proper heart function, and in severe cases, can be fatal.

Organ Systems and the Citric Acid Cycle

The citric acid cycle is not confined to a specific organ system; it is a ubiquitous metabolic pathway present in virtually every cell that utilizes oxygen to produce energy. This widespread presence underscores its fundamental role in both anabolic and catabolic cellular processes across all organ systems.

Function of the Citric Acid Cycle: Step-by-Step within the Mitochondria

The citric acid cycle is a series of eight enzyme-catalyzed reactions that occur sequentially in the mitochondrial matrix. Each step plays a critical role in the overall function of the cycle:

1. Citrate Synthesis:

Citrate synthase, located in the mitochondrial matrix, catalyzes the condensation of acetyl CoA and oxaloacetate to form citrate. This initial step is highly exergonic (delta-G-prime of -7.7 Kcal/M), making it essentially irreversible and strongly favoring citrate formation. Citrate synthase activity is regulated by substrate availability and product feedback. Citrate acts as a competitive inhibitor, while oxaloacetate binding increases the enzyme’s affinity for acetyl-CoA. Notably, citrate also serves as a metabolic signal, inhibiting phosphofructokinase-1 in glycolysis and activating acetyl-CoA carboxylase for fatty acid synthesis, highlighting the interconnectedness of metabolic pathways.5

2. Isomerization of Citrate:

Aconitase, another mitochondrial matrix enzyme, catalyzes the reversible isomerization of citrate to isocitrate. This reaction involves a dehydration step followed by a hydration step, with cis-aconitate as an intermediate. Aconitase contains an iron-sulfur cluster that is crucial for facilitating the hydroxyl group migration during this isomerization.6

3. Oxidative Decarboxylation of Isocitrate:

Isocitrate dehydrogenase, found in the mitochondrial matrix, catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate. This is a rate-limiting step of the TCA cycle and the first reaction that produces a reduced coenzyme (NADH) and releases carbon dioxide (CO2). The reaction is essentially irreversible due to the release of CO2. Isocitrate dehydrogenase is allosterically regulated: ADP and calcium ions activate it, while ATP and NADH inhibit it.7

4. Oxidative Decarboxylation of Alpha-ketoglutarate:

The alpha-ketoglutarate dehydrogenase complex, located in the mitochondrial matrix, catalyzes the conversion of alpha-ketoglutarate to succinyl-CoA. This multi-enzyme complex, similar in mechanism to pyruvate dehydrogenase complex, also produces NADH, CO2, and H+. The complex utilizes five cofactors: thiamine pyrophosphate, lipoic acid, coenzyme A, NAD+, and FAD. Alpha-ketoglutarate dehydrogenase complex activity is inhibited by its products: succinyl-CoA, NADH, and ATP.8,9

5. Cleavage of Succinyl Coenzyme A:

Succinate thiokinase (also known as succinyl-CoA synthetase), present in the mitochondrial matrix, catalyzes the reversible conversion of succinyl-CoA to succinate. This reaction is coupled to the phosphorylation of GDP to GTP (or ADP to ATP in some tissues), a substrate-level phosphorylation similar to reactions in glycolysis.10

6. Oxidation of Succinate:

Succinate dehydrogenase, uniquely located on the inner mitochondrial membrane (and also known as Complex II of the electron transport chain), catalyzes the oxidation of succinate to fumarate. In this reaction, FAD is reduced to FADH2, which remains bound to the enzyme. Succinate dehydrogenase directly links the TCA cycle to the electron transport chain by feeding electrons into the ubiquinone pool.11

7. Hydration of Fumarate:

Fumarase (or fumarate hydratase), found in the mitochondrial matrix, catalyzes the reversible hydration of fumarate to malate. Fumarate is also produced in the urea cycle, illustrating the interconnectedness of different metabolic pathways.12

8. Oxidation of Malate:

Malate dehydrogenase, located in the mitochondrial matrix, catalyzes the final step of the TCA cycle: the reversible oxidation of malate to oxaloacetate. This reaction generates the final NADH of the cycle and regenerates oxaloacetate, which is essential to initiate another cycle by reacting with acetyl-CoA. Although the reaction has a positive delta-G-prime under standard conditions, it is driven forward in vivo by the consumption of oxaloacetate in the citrate synthase reaction.13

Cataplerotic and Anaplerotic Roles of the Citric Acid Cycle

The citric acid cycle is not only a catabolic pathway but also plays crucial roles in both cataplerotic and anaplerotic processes:

Cataplerotic Processes: Intermediates of the citric acid cycle can be drawn off (cataplerosis) to serve as precursors in various biosynthetic pathways. For instance, citrate can be transported out of the mitochondria to the cytoplasm for fatty acid synthesis, succinyl-CoA is used in heme biosynthesis, alpha-ketoglutarate and oxaloacetate are precursors for amino acid synthesis, alpha-ketoglutarate is involved in purine and neurotransmitter synthesis, and malate can be used for gluconeogenesis.14,4

Anaplerotic Processes: To replenish TCA cycle intermediates that are removed for biosynthesis (cataplerosis), anaplerotic reactions are essential. Pyruvate carboxylase, present in the mitochondrial matrix, catalyzes the carboxylation of pyruvate to oxaloacetate, a major anaplerotic reaction in many tissues, ensuring the cycle continues to operate. In the liver, alpha-ketoglutarate can be replenished through oxidative deamination or transamination of glutamate.15,4

Related Testing for Citric Acid Cycle Function

Evaluating mitochondrial function often involves assessing the citric acid cycle. For example, mitochondrial dysfunction is a key feature of nonalcoholic fatty liver disease (NAFLD). Researchers are exploring the use of plasma isocitrate and citrate levels as potential indicators of mitochondrial alterations, highlighting the potential of mitochondrial metabolite profiling for understanding mitochondrial function.

Pathophysiology of Citric Acid Cycle Dysfunction

Mitochondrial dysfunction, impacting the Krebs cycle, can arise from various factors. Excess calorie intake can overwhelm the cycle’s capacity to balance degradation and availability of molecules, leading to metabolic imbalances. Obesity is often associated with mitochondrial dysfunction, characterized by increased oxidative stress, reactive oxygen species production, inflammation, and apoptosis.

Furthermore, mitochondrial dysfunction can also result from excessive metabolic demand. In animal models of Duchenne muscular dystrophy, elevated mitochondrial metabolites are observed in tissues like the diaphragm, peripheral muscles, and the central nervous system, possibly due to increased oxidative stress.

Clinical Significance of Citric Acid Cycle Defects

Defects in enzymes and processes related to the citric acid cycle have significant clinical implications, leading to various disorders:

1. Pyruvate Dehydrogenase Complex Deficiency:

This neurodegenerative disorder results from mutations affecting the pyruvate decarboxylase subunit of PDC, impairing the conversion of pyruvate to acetyl-CoA. The buildup of pyruvate is then shunted to lactate production, causing potentially fatal lactic acidosis. Symptoms can include neonatal lethargy, hypotonia, muscle spasticity, neurodegeneration, and early death.16,17,18

2. Leigh Syndrome:

Subacute necrotizing encephalomyelopathy, or Leigh syndrome, is a severe neurological disorder caused by gene mutations affecting proteins of the PDC and other mitochondrial energy pathways. Common early signs in children include loss of previously acquired motor skills, loss of head control, poor suckling, recurrent vomiting, and appetite loss.19,20,21

3. Thiamine Deficiency:

Thiamine deficiency can mimic pyruvate dehydrogenase complex deficiency by also shunting pyruvate to lactate, leading to metabolic acidosis. However, in this case, the issue is a lack of the active form of thiamine (thiamine pyrophosphate) rather than a PDC defect. Thiamine deficiency manifests as beriberi, with dry beriberi characterized by peripheral neuropathy and wet beriberi affecting the cardiovascular system, leading to heart failure and edema.22,23

4. Fumarase Deficiency:

Fumarase deficiency is a rare autosomal recessive disorder of the TCA cycle caused by mutations in the FH gene, leading to a deficiency of fumarase and accumulation of fumaric acid. This condition primarily affects the nervous system, causing severe developmental delay, microcephaly, hypotonia, encephalopathy, seizures, and failure to thrive.24,25,26,27

5. Mutations of Isocitrate Dehydrogenase:

Mutations in isocitrate dehydrogenase (IDH) have been found in various cancers, including leukemia, gliomas, and sarcomas. Mutant IDH enzymes catalyze the production of 2-hydroxyglutarate instead of alpha-ketoglutarate. 2-hydroxyglutarate is an oncometabolite that can contribute to cancer development by causing DNA and histone hypermethylation. It also serves as a potential biomarker for cancer in patients with metabolic disorders.28,29,7,30

Review Questions

(Figure 1)

Figure 1: Krebs Cycle. Illustration of the Krebs Cycle, highlighting the cyclical series of reactions and key intermediates within the mitochondrial matrix.

References

  1. Cavalcanti JH, Esteves-Ferreira AA, Quinhones CG, Pereira-Lima IA, Nunes-Nesi A, Fernie AR, Araújo WL. Evolution and functional implications of the tricarboxylic acid cycle as revealed by phylogenetic analysis. Genome Biol Evol. 2014 Oct 01;6(10):2830-48. [PMC free article: PMC4224347] [PubMed: 25274566]
  2. Sousa JS, D’Imprima E, Vonck J. Mitochondrial Respiratory Chain Complexes. Subcell Biochem. 2018;87:167-227. [PubMed: 29464561]
  3. Spydevold S, Davis EJ, Bremer J. Replenishment and depletion of citric acid cycle intermediates in skeletal muscle. Indication of pyruvate carboxylation. Eur J Biochem. 1976 Dec;71(1):155-65. [PubMed: 1009946]
  4. Haddad A, Mohiuddin SS. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Biochemistry, Citric Acid Cycle. [PubMed: 31082116]
  5. Wiegand G, Remington SJ. Citrate synthase: structure, control, and mechanism. Annu Rev Biophys Biophys Chem. 1986;15:97-117. [PubMed: 3013232]
  6. Pechter KB, Meyer FM, Serio AW, Stülke J, Sonenshein AL. Two roles for aconitase in the regulation of tricarboxylic acid branch gene expression in Bacillus subtilis. J Bacteriol. 2013 Apr;195(7):1525-37. [PMC free article: PMC3624536] [PubMed: 23354745]
  7. Al-Khallaf H. Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. Cell Biosci. 2017;7:37. [PMC free article: PMC5543436] [PubMed: 28785398]
  8. Krebs HA, Johnson WA. Metabolism of ketonic acids in animal tissues. Biochem J. 1937 Apr;31(4):645-60. [PMC free article: PMC1266984] [PubMed: 16746382]
  9. Tretter L, Adam-Vizi V. Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philos Trans R Soc Lond B Biol Sci. 2005 Dec 29;360(1464):2335-45. [PMC free article: PMC1569585] [PubMed: 16321804]
  10. Phillips D, Aponte AM, French SA, Chess DJ, Balaban RS. Succinyl-CoA synthetase is a phosphate target for the activation of mitochondrial metabolism. Biochemistry. 2009 Aug 04;48(30):7140-9. [PMC free article: PMC2766921] [PubMed: 19527071]
  11. Rutter J, Winge DR, Schiffman JD. Succinate dehydrogenase – Assembly, regulation and role in human disease. Mitochondrion. 2010 Jun;10(4):393-401. [PMC free article: PMC2874626] [PubMed: 20226277]
  12. Yogev O, Yogev O, Singer E, Shaulian E, Goldberg M, Fox TD, Pines O. Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response. PLoS Biol. 2010 Mar 09;8(3):e1000328. [PMC free article: PMC2834712] [PubMed: 20231875]
  13. Minárik P, Tomásková N, Kollárová M, Antalík M. Malate dehydrogenases–structure and function. Gen Physiol Biophys. 2002 Sep;21(3):257-65. [PubMed: 12537350]
  14. Hertz L, Hertz E. Cataplerotic TCA cycle flux determined as glutamate-sustained oxygen consumption in primary cultures of astrocytes. Neurochem Int. 2003 Sep-Oct;43(4-5):355-61. [PubMed: 12742079]
  15. Gibala MJ, MacLean DA, Graham TE, Saltin B. Anaplerotic processes in human skeletal muscle during brief dynamic exercise. J Physiol. 1997 Aug 01;502 ( Pt 3)(Pt 3):703-13. [PMC free article: PMC1159539] [PubMed: 9279819]
  16. Gupta N, Rutledge C. Pyruvate Dehydrogenase Complex Deficiency: An Unusual Cause of Recurrent Lactic Acidosis in a Paediatric Critical Care Unit. J Crit Care Med (Targu Mures). 2019 Apr;5(2):71-75. [PMC free article: PMC6534940] [PubMed: 31161145]
  17. Patel KP, O’Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol Genet Metab. 2012 Jul;106(3):385-94. [PMC free article: PMC4003492] [PubMed: 22896851]
  18. Brown GK, Otero LJ, LeGris M, Brown RM. Pyruvate dehydrogenase deficiency. J Med Genet. 1994 Nov;31(11):875-9. [PMC free article: PMC1016663] [PubMed: 7853374]
  19. Rahman S, Thorburn D. Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. University of Washington, Seattle; Seattle (WA): Oct 1, 2015. [PMC free article: PMC320989] [PubMed: 26425749]
  20. Ball M, Thorburn DR, Rahman S. Mitochondrial DNA-Associated Leigh Syndrome Spectrum. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. University of Washington, Seattle; Seattle (WA): Oct 30, 2003. [PMC free article: PMC1173] [PubMed: 20301352]
  21. Ruhoy IS, Saneto RP. The genetics of Leigh syndrome and its implications for clinical practice and risk management. Appl Clin Genet. 2014;7:221-34. [PMC free article: PMC4235479] [PubMed: 25419155]
  22. Dhir S, Tarasenko M, Napoli E, Giulivi C. Neurological, Psychiatric, and Biochemical Aspects of Thiamine Deficiency in Children and Adults. Front Psychiatry. 2019;10:207. [PMC free article: PMC6459027] [PubMed: 31019473]
  23. Wiley KD, Gupta M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 17, 2023. Vitamin B1 (Thiamine) Deficiency. [PubMed: 30725889]
  24. Ryder B, Moore F, Mitchell A, Thompson S, Christodoulou J, Balasubramaniam S. Fumarase Deficiency: A Safe and Potentially Disease Modifying Effect of High Fat/Low Carbohydrate Diet. JIMD Rep. 2018;40:77-83. [PMC free article: PMC6122040] [PubMed: 29052812]
  25. Coman D, Kranc KR, Christodoulou J. Fumarate Hydratase Deficiency. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. University of Washington, Seattle; Seattle (WA): Jul 5, 2006. [PMC free article: PMC1506] [PubMed: 20301679]
  26. Gellera C, Uziel G, Rimoldi M, Zeviani M, Laverda A, Carrara F, DiDonato S. Fumarase deficiency is an autosomal recessive encephalopathy affecting both the mitochondrial and the cytosolic enzymes. Neurology. 1990 Mar;40(3 Pt 1):495-9. [PubMed: 2314594]
  27. Ezgu F, Krejci P, Wilcox WR. Mild clinical presentation and prolonged survival of a patient with fumarase deficiency due to the combination of a known and a novel mutation in FH gene. Gene. 2013 Jul 25;524(2):403-6. [PubMed: 23612258]
  28. Wu F, Cheng G, Yao Y, Kogiso M, Jiang H, Li XN, Song Y. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer. Med Chem. 2018;14(7):715-724. [PMC free article: PMC6205205] [PubMed: 29792149]
  29. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010 Jul 07;102(13):932-41. [PMC free article: PMC2897878] [PubMed: 20513808]
  30. Guo C, Pirozzi CJ, Lopez GY, Yan H. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol. 2011 Dec;24(6):648-52. [PMC free article: PMC3640434] [PubMed: 22002076]

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *